🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is — my results so far Page 7

Can we talk about how SLOW the FDA is — my results so far

NurseAsh_DET Tue, Nov 18, 2025 at 7:47 PM 43 replies 1,294 viewsPage 7 of 9
TomTeleRx
Member
189
678
Feb 2025
Delaware
Feb 15, 2026 at 9:33 PM#31
NurseAsh_DET said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Last edited: Feb 15, 2026 at 10:33 PM
12 10pete_manc_UK, anna.melb_AU, mark_tokyo and 9 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Feb 22, 2026 at 8:39 PM#32
NurseAsh_DET said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Feb 22, 2026 at 9:39 PM
13 11Dr.AddMedPHL, newstart_MO, mia_MS2 and 10 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Mar 1, 2026 at 7:41 PM#33
NurseAsh_DET said:
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have.

Thank you for spelling out the reasoning rather than just the conclusion. Adding it to my notes with a link back to this thread.

14 12DadBodDave, AmyNC_wife, SkepticalSean and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Mar 8, 2026 at 6:39 PM#34

Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

15 13ricardo_MIA, BrianDallas92, labquiet_amy and 12 others
Reply Quote Save Share Report
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Mar 15, 2026 at 5:33 PM#35
PeptideChemSF said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Same pattern here, and in the same order.

Last edited: Mar 15, 2026 at 11:33 PM
16 14sophie_paris, mel_PDX, Dr.AddMedPHL and 13 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register